The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations

At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, and described the different testing modalities for molecular mar...

Descripción completa

Detalles Bibliográficos
Autor principal: Persinger, Rasheda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2021
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087227/
https://www.ncbi.nlm.nih.gov/pubmed/34084579
http://dx.doi.org/10.6004/jadpro.2021.12.3.17
_version_ 1783686628630331392
author Persinger, Rasheda
author_facet Persinger, Rasheda
author_sort Persinger, Rasheda
collection PubMed
description At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, and described the different testing modalities for molecular markers.
format Online
Article
Text
id pubmed-8087227
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-80872272021-06-02 The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations Persinger, Rasheda J Adv Pract Oncol Meeting Reports At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, and described the different testing modalities for molecular markers. Harborside Press LLC 2021-04 2021-04-01 /pmc/articles/PMC8087227/ /pubmed/34084579 http://dx.doi.org/10.6004/jadpro.2021.12.3.17 Text en © 2021 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Persinger, Rasheda
The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations
title The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations
title_full The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations
title_fullStr The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations
title_full_unstemmed The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations
title_short The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations
title_sort landscape of the advanced nsclc treatment paradigm: molecular testing and actionable mutations
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087227/
https://www.ncbi.nlm.nih.gov/pubmed/34084579
http://dx.doi.org/10.6004/jadpro.2021.12.3.17
work_keys_str_mv AT persingerrasheda thelandscapeoftheadvancednsclctreatmentparadigmmoleculartestingandactionablemutations
AT persingerrasheda landscapeoftheadvancednsclctreatmentparadigmmoleculartestingandactionablemutations

Ejemplares similares